Key result
Bevifibatide cuts 30-day major ischemic events ~43% vs placebo in ACS patients undergoing PCI.
Why the study?
Does bevifibatide reduce the composite of death, MI, urgent revascularization, need for antithrombotic rescue, and no-reflow/slow flow in ACS patients undergoing PCI?
RCT (n=1,442)
Double-blind
Randomized
Yes
Does bevifibatide reduce the composite of death, MI, urgent revascularization, need for antithrombotic rescue, and no-reflow/slow flow in ACS patients undergoing PCI?
Bevifibatide, a novel glycoprotein IIb/IIIa inhibitor, significantly reduces ischemic complications and no-reflow in ACS patients undergoing PCI, with an acceptable bleeding profile.
Supports bevifibatide in ACS PCI to lower ischemic events; confirms efficacy of a new GP IIb/IIIa inhibitor in an RCT.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Simon Fung (2026) conducted an RCT in Acute coronary syndrome (ACS) (n=1,442). Bevifibatide vs. Placebo was evaluated on Composite of death, myocardial infarction, acute target vessel revascularization, need for antithrombotic therapy, and no-reflow/severe slow flow at 30 days post-PCI (HR 0.57, 95% CI 0.35-0.94, p=0.026). Bevifibatide reduced the 30-day composite endpoint of death, myocardial infarction, acute target vessel revascularization, need for antithrombotic therapy, and no-reflow/slow flow by 43% (HR 0.57) compared to placebo in ACS patients undergoing PCI.
Synapse has enriched 5 related papers. Consider them for comparative context: